Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the
developed world. Despite available treatment, 25% of children in San Diego County
appropriately treated for KD develop coronary artery abnormalities that could lead to
complications later in life, including heart attack. Although investigators can identify
children with KD that have these coronary artery abnormalities, there is no approved
additional treatment to decrease coronary artery inflammation and arrest or prevent damage to
the coronary arteries. Inflammation and damage to the arterial wall is central to these
coronary artery abnormalities. Statins, a class of drugs that is known for lowering
cholesterol, have also been shown to decrease inflammation in general as well as at the level
of the vessel wall. Therefore, the investigators propose to study the safety of the drug
atorvastatin in children with coronary artery abnormalities from KD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
Children's Hospital Colorado University of Colorado, Denver